Modality
Gene Therapy
MOA
BTKi
Target
PD-1
Pathway
Angiogenesis
Narcolepsy
Development Pipeline
Preclinical
Sep 2023
→ May 2027
PreclinicalCurrent
NCT06997459
2,119 pts·Narcolepsy
2023-09→2027-05·Active
2,119 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-05-051.1y awayInterim· Narcolepsy
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
Preclinical
Active
Catalysts
Interim
2027-05-05 · 1.1y away
Narcolepsy
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06997459 | Preclinical | Narcolepsy | Active | 2119 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Ivosotorasib | Vertex Pharma | Preclinical | CD38 |